PT2914254T - Terapias de combinação para tratar cancros quimiorresistentes - Google Patents

Terapias de combinação para tratar cancros quimiorresistentes

Info

Publication number
PT2914254T
PT2914254T PT138519715T PT13851971T PT2914254T PT 2914254 T PT2914254 T PT 2914254T PT 138519715 T PT138519715 T PT 138519715T PT 13851971 T PT13851971 T PT 13851971T PT 2914254 T PT2914254 T PT 2914254T
Authority
PT
Portugal
Prior art keywords
combination therapies
therapies
combination
Prior art date
Application number
PT138519715T
Other languages
English (en)
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of PT2914254T publication Critical patent/PT2914254T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245Amino benzoic acid types, e.g. procaine, novocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT138519715T 2012-10-30 2013-10-30 Terapias de combinação para tratar cancros quimiorresistentes PT2914254T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261720346P 2012-10-30 2012-10-30

Publications (1)

Publication Number Publication Date
PT2914254T true PT2914254T (pt) 2020-04-02

Family

ID=50628036

Family Applications (1)

Application Number Title Priority Date Filing Date
PT138519715T PT2914254T (pt) 2012-10-30 2013-10-30 Terapias de combinação para tratar cancros quimiorresistentes

Country Status (15)

Country Link
US (2) US20150258068A1 (pt)
EP (2) EP2914254B1 (pt)
JP (1) JP6343285B2 (pt)
CA (1) CA2927565C (pt)
CY (1) CY1123043T1 (pt)
DK (1) DK2914254T3 (pt)
ES (1) ES2774296T3 (pt)
HR (1) HRP20200521T1 (pt)
HU (1) HUE048584T2 (pt)
LT (1) LT2914254T (pt)
PL (1) PL2914254T3 (pt)
PT (1) PT2914254T (pt)
RS (1) RS60122B1 (pt)
SI (1) SI2914254T1 (pt)
WO (1) WO2014070948A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0414581C1 (pt) 2003-09-22 2021-05-25 Mei Pharma Inc composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
AR108257A1 (es) * 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
EP3749330A4 (en) 2018-02-06 2021-11-17 The General Hospital Corporation REPEAT RNA AS A BIOMARKER OF TUMOR IMMUNE REACTION
EA202191503A1 (ru) * 2018-11-30 2021-11-15 Мей Фарма, Инк. Комбинированные терапии для мдс высокого и очень высокого риска
JP7115401B2 (ja) 2019-04-10 2022-08-09 株式会社デンソー モータ

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US20100098691A1 (en) * 2001-01-24 2010-04-22 S'bio Pte Ltd Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
AU2003215112A1 (en) 2002-02-07 2003-09-02 Axys Pharmaceuticals Novel bicyclic hydroxamates as inhibitors of histone deacetylase
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
NZ594108A (en) * 2005-09-08 2012-12-21 S Bio Pte Ltd Benzimidazole compounds useful as inhibitors of Histone Deacetylase (HDAC)
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
JP2012503651A (ja) * 2008-09-26 2012-02-09 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ 3−デアザネプラノシン誘導体

Also Published As

Publication number Publication date
JP6343285B2 (ja) 2018-06-13
EP2914254A1 (en) 2015-09-09
HRP20200521T1 (hr) 2020-08-07
CA2927565A1 (en) 2014-05-08
JP2016501838A (ja) 2016-01-21
CA2927565C (en) 2021-05-18
LT2914254T (lt) 2020-04-27
ES2774296T3 (es) 2020-07-20
EP3662911A1 (en) 2020-06-10
US20210100775A1 (en) 2021-04-08
RS60122B1 (sr) 2020-05-29
CY1123043T1 (el) 2021-10-29
EP2914254A4 (en) 2016-06-29
HUE048584T2 (hu) 2020-08-28
WO2014070948A1 (en) 2014-05-08
SI2914254T1 (sl) 2020-07-31
EP2914254B1 (en) 2020-01-08
DK2914254T3 (en) 2020-03-30
PL2914254T3 (pl) 2020-09-07
US20150258068A1 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
DK3327112T3 (en) Agse-deficient stamme
EP2934531A4 (en) COMBINATION
EP2754580A4 (en) DUMP TRUCK
DK2830816T3 (en) Hidtil ukendt coatingkoncept
EP2935220A4 (en) PERI-carbinol
EP2914254A4 (en) COMBINATION THERAPIES
PT2802471T (pt) Autocarro descapotável
HK1209108A1 (en) Oxazolidin-2-one-pyrimidine derivatives -2--
IL236699B (en) Carbamate-benzoxazinones
EP2911673A4 (en) COMBINATION
EP2920142A4 (en) MÉTHANOFULLERRÈNES
EP2812698A4 (en) TIME RESOLVED FREIGHT AND DOUBLE ACCEPTOR
HK1206738A1 (en) Azaindolines
EP2906215A4 (en) SUITS
EP2920157A4 (en) DI MACRO CYCLEN
EP2873363A4 (en) DIOPSIMETER
EP2834250A4 (de) Lithiumsilikate
EP2925728A4 (en) COMBINATION
GB201214493D0 (en) Therapies
GB2499853B (en) MicBooth
EP2908815A4 (en) COMBINATION
EP2908816A4 (en) ASSOCIATION
GB201216178D0 (en) Combination
GB201215818D0 (en) Anti-wrapping unit
GB201221267D0 (en) Totto